Gadeta
Gadeta is a Utrecht-based biotech developing engineered T-cell receptor immunotherapies for cancer. Founded in 2015, it is a preclinical, venture-funded R&D company backed by Baxalta Ventures, Medicxi, Utrecht Holdings, and Kite Pharma.
- Company typePrivate
- Founded2015
- HeadquartersUtrecht, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingServices
Gadeta firmographics
Firmographics- Name
- Gadeta
- Website
- https://gadeta.nl
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Gadeta is a Utrecht-based biotech developing engineered T-cell receptor immunotherapies for cancer. Founded in 2015, it is a preclinical, venture-funded R&D company backed by Baxalta Ventures, Medicxi, Utrecht Holdings, and Kite Pharma.
- Ownership category
- akta.pro rank
Gadeta industry classification
Industry- Product category
- Cancer Cell Therapy / Gamma Delta T Cell Immunotherapy R&D
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Gadeta is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
Gadeta business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Gadeta product offering
Product offeringCore offering
Gadeta is a research and development biopharmaceutical company developing immunotherapies for cancer, centered on a proprietary gamma delta (γδ) T cell receptor technology platform. The company engineers γδ T cell receptors to create novel cell therapies targeting solid and hematological malignancies, with a focus on allogeneic, off-the-shelf treatment approaches. Its work combines TCR discovery, receptor engineering, and preclinical cell therapy development in collaboration with strategic pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Products and services
- Gamma delta T cell receptor (γδ TCR) immunotherapy platform A proprietary research and development platform based on gamma delta T cell receptor engineering, used to discover and develop novel allogeneic cancer cell therapies targeting solid and hematological malignancies. Intended for strategic partnership and licensing with pharmaceutical companies developing oncology pipelines.
Companies that use Gadeta
Customer profileIdeal customer profiles1 record
Gadeta technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gadeta partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- GreenhostminorGreenhost provides web hosting services for Gadeta's website (gadeta.nl). This is an infrastructure/vendor relationship where Greenhost acts as the hosting provider.
Gadeta competitors and assessment
Company assessmentDirect peers
- Adaptimmune: Clinical-stage company developing TCR-T cell therapies for solid tumors. Most direct comparable to Gadeta given overlapping TCR-engineered autologous cell therapy modality and oncology focus.
- TC BioPharm: Develops allogeneic and autologous gamma-delta T-cell therapies for cancer. Closest mechanistic peer to Gadeta, as both pursue gamma-delta biology in oncology cell therapy.
- Immatics: Develops TCR-based immunotherapies against tumor-specific antigens. Comparable on the TCR-T modality and oncology focus, with a broader multi-platform approach.
Emerging players
- Cellectis: Pioneers allogeneic CAR-T and gene-edited cell therapies using TALEN. Comparable as an engineered cell therapy developer, though focused on allogeneic CAR-T rather than TCR-T.
- Fate Therapeutics: Develops iPSC-derived NK and T-cell therapies. Comparable as an engineered cell therapy platform company pursuing off-the-shelf oncology indications.
- Immunocore: Develops TCR-based ImmTAC molecules for oncology. Comparable as a TCR-based oncology platform, though delivers TCRs as soluble biologics rather than cell therapies.
- Precision BioSciences: Develops in vivo and ex vivo gene-edited cell therapies using ARCUS nucleases. Comparable as a gene-edited cell therapy developer in oncology.
Broad incumbents
- Allogene Therapeutics: Leading allogeneic CAR-T developer. Comparable as a large, well-capitalized engineered cell therapy company competing for talent, sites, and partnerships in the same oncology cell therapy space.
- CRISPR Therapeutics: Gene-edited cell therapy developer (Casgevy partner with Vertex). Comparable as a major engineered cell therapy player and potential competitor for clinical-stage assets and partnership capital.
- Kite Pharma (a Gilead Company): Commercial leader in autologous CAR-T cell therapy and an existing investor in Gadeta. Comparable as the strategic acquirer/partner with manufacturing scale that anchors cell therapy economics in oncology.
Market position
Customer concentration
Gadeta financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gadeta leadership team
Management profileNumber of profiles
Profiles4 records
Gadeta funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gadeta M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gadeta
What does Gadeta do?
Gadeta is a research and development biopharmaceutical company developing immunotherapies for cancer, centered on a proprietary gamma delta (γδ) T cell receptor technology platform. The company engineers γδ T cell receptors to create novel cell therapies targeting solid and hematological malignancies, with a focus on allogeneic, off-the-shelf treatment approaches. Its work combines TCR discovery, receptor engineering, and preclinical cell therapy development in collaboration with strategic pharmaceutical partners.
When was Gadeta founded?
Gadeta was founded in 2015. It employs 11 to 50 people.
Where is Gadeta based?
Gadeta is headquartered in Utrecht, Netherlands, in the Europe region.
Who are Gadeta's main competitors?
Direct peers on record are Adaptimmune, TC BioPharm and Immatics. Emerging players are Cellectis, Fate Therapeutics, Immunocore and Precision BioSciences. Broad incumbents are Allogene Therapeutics, CRISPR Therapeutics and Kite Pharma (a Gilead Company).
Does Gadeta have an API?
No public API is recorded for Gadeta.
What industry is Gadeta in?
Gadeta's product category is Cancer Cell Therapy / Gamma Delta T Cell Immunotherapy R&D. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 541714 and its SIC code is 2836.